Results 71 to 80 of about 1,830,783 (287)
DeCoST: A New Approach in Drug Repurposing From Control System Theory
Frontiers in Pharmacology, 2018 In this paper, we propose DeCoST (Drug Repurposing from Control System Theory) framework to apply control system paradigm for drug repurposing purpose.
Thanh M. Nguyen +6 more
doaj +1 more source
Electrospun Wood‐Derived Biopolymers as Electrodes in Electrochemical Energy Storage Technologies
Advanced Functional Materials, EarlyView.Electrospinning transforms wood‐derived cellulose and lignin into architecturally defined, binder‐free carbon electrodes with tuneable porosity and functionality. This review shows how fibre design enables decoupled charge and mass transport, enhancing performance across battery systems, while identifying key challenges in spinnability, scalability ...
Michael W. Thielke +3 more
wiley +1 more source
The processes of reform in Victoria’s alcohol and other drug sector, 2011-2014 [PDF]
, 2014 This paper explores issues and concerns related to the 2014 alcohol and other drug sector recommissioning process in Victoria. Overview In mid-2014, the Victorian Alcohol and Drug Association approached the Drug Policy Modelling Program, at the ...
Drug Policy Modelling Program
core
Chitin‐Derived Carbon‐Metal Functional Materials
Advanced Functional Materials, EarlyView.Functional carbon materials are synthesized from combination of biopolymer (chitin) and iron precursors. The resultant material exhibits superior surface area and adsorptive properties compared to carbon materials synthesized directly from pure chitin.
Herry Fang +7 more
wiley +1 more source
Protein‐Nanoarchitectures for Low‐Field Intracellular Electro‐Immunomodulation
Advanced Functional Materials, EarlyView.DHQ‐SDH‐mediated binding of AuNPs drives the formation of interconnected, chain‐like nanoarchitectures with enhanced electrical conductivity. These conductive assemblies undergo macrophage uptake and enable low‐field electrical stimulation, promoting M1‐to‐M2 phenotypic switching with decreased iNOS and increased CD206 expression. Such protein‐mediated
Viktoriya Pakharenko +7 more
wiley +1 more source
Structure-based drug repurposing : Traditional and advanced AI/ML-aided methods
, 2022 The current global health emergency in the form of the Coronavirus 2019 (COVID-19) pandemic has highlighted the need for fast, accurate, and efficient drug discovery pipelines.
Priyakumar, U. Deva, +2 more
core +1 more source
Advanced Healthcare Materials, EarlyView.Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj +23 more
wiley +1 more source
Therapeutic innovation in drug repurposing: Challenges and opportunities [PDF]
Drug repurposing leverages existing drugs for new therapeutic uses, offering significant opportunities but facing challenges such as financial and regulatory barriers and the need for robust evidence for an efficient clinical development plan. This paper
UCL Repurposing TIN, Committee +4 more
core +1 more source
A bibliometric review of drug repurposing [PDF]
, 2018 © 2018 Elsevier Ltd We have conducted a bibliometric review of drug repurposing by scanning >25 million papers in PubMed and using text-mining methods to gather, count and analyze chemical–disease therapeutic relationships.
core
Gliptin Repurposing for COVID-19 [PDF]
, 2020 De novo drug discovery of any therapeutic modality (e.g. antibodies, vaccines or small molecules) historically takes years from idea/preclinic to the market and it is therefore not a short-term solution for the current SARS-CoV-2 pandemic.
Constantinos, Neochoritis +5 more
core +1 more source